Clinical review report. Lumacaftor/Ivacaftor (Orkambi) (Vertex Pharmaceuticals (Canada) Incorporated).
Orkambi is a fixed-dose combination tablet containing lumacaftor and ivacaftor (LUM/IVA). It is indicated for the treatment of cystic fibrosis (CF) in patients aged six years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane regulator (CFTR) gene. This is the...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Edition: | Version: Final (with redactions). |
| Series: | Common drug review clinical review report.
|
| Subjects: |
